The patent covers a central facet of the company’s core technology in oral delivery of proteins.
Oramed CEO Nadav Kidron said the Israeli patent covers a fundamental aspect of the company’s technology.
"Its approval, along with the recent approval of the same patent in Australia, will help pave the way to further validations of our technology," Kidron added.
An oral delivery system for current injectable medications may increase patient compliance thus leading to a favorable prognosis in the condition being treated, as well as reducing overall costs to the healthcare system in the long run.